Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Acromegaly
Related studies linked through entity extraction aliases.
Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
- Status
- COMPLETED
- Phase
- N/A
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- Status
- COMPLETED
- Phase
- N/A
Lanreotide Levels in Acromegaly
- Status
- UNKNOWN
- Phase
- N/A
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
- Status
- COMPLETED
- Phase
- NA
Open Label Study of Octreotide Implant in Patients With Acromegaly
- Status
- COMPLETED
- Phase
- PHASE2
Non Interventional Study For Patients Treated With Somavert®
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
- Status
- TERMINATED
- Phase
- PHASE3
Non Interventional Post Marketing Programme in Acromegaly
- Status
- COMPLETED
- Phase
- N/A
Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
- Status
- COMPLETED
- Phase
- N/A
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
- Status
- COMPLETED
- Phase
- PHASE4
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
- Status
- COMPLETED
- Phase
- PHASE3
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
- Status
- COMPLETED
- Phase
- N/A
Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance
- Status
- COMPLETED
- Phase
- N/A
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Status
- COMPLETED
- Phase
- N/A
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
- Status
- COMPLETED
- Phase
- NA
Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
- Status
- COMPLETED
- Phase
- N/A
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
- Status
- COMPLETED
- Phase
- PHASE4
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
- Status
- TERMINATED
- Phase
- PHASE3
Inter-Assay Growth Hormone and IGF-I Variability
- Status
- WITHDRAWN
- Phase
- N/A